

6 May 2026

Botanix announces change of address

Philadelphia PA and Phoenix AZ, 6 May 2026: Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), announces that its registered office, principal place of business and postal address will change with immediate effect to:

Botanix Pharmaceuticals Limited
Level 23, Tower 5, Collins Square
727 Collins Street
Melbourne, VIC 3008

All other details remain unchanged.

Release authorised by

Vince Ippolito
Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries
Corporate Communications
Botanix Pharmaceuticals
P: +61 8 6285 0083
info@botanixpharma.com

Investor enquiries
Hannah Howlett
P: +61 4 5064 8064
investors@botanixpharma.com

Media enquiries
Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital